Birmingham researchers have received £230k from Cancer Research Horizons to develop a prototype test for monitoring people with MGUS (monoclonal gammopathy of unknown significance), a precursor to ...
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma-cell disorder present in approximately 5% of the general population over the age of 50 years. MGUS is characterized ...
Researchers in Birmingham have secured £230,000 in translational funding from Cancer Research Horizons to create a prototype test aimed at monitoring individuals at risk of developing multiple myeloma ...
Patients with monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma (MM), can progress from low- or intermediate-risk to MM in just 5 years, according to ...
Individuals with low-risk or intermediate-risk monoclonal gammopathy of undetermined significance (MGUS) may convert to high-risk MGUS and progress to multiple myeloma within 5 years, researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results